Opinion|Videos|September 26, 2024
MANIFEST-2: Pelabresib in Myelofibrosis: MOA, Study Design, and Spleen Volume Reduction
Author(s)David M. Swoboda, MD, Andrew T. Kuykendall, MD
Panelists discuss the MANIFEST-2 trial of pelabresib in myelofibrosis, focusing on its mechanism of action (MOA), study design, and impact on spleen volume reduction.
Advertisement
Episodes in this series
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Nab-Sirolimus Regimens Show Promise in HR+/HER2-Negative Breast Cancer
2
Spotlighting the Top 10 FDA Oncology Approvals in 2025
3
Ivosidenib Combo Shows Preliminary Activity in IDH1-Mutated AML
4
What’s New in Hematology/Oncology? Discussing the 2025 ASH Annual Meeting
5